Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc.
Funding for the research and method development provided by the National Institutes of Health (NIH)
SeqLL Inc.
Gainers
RenovoRx, Inc. (NASDAQ: RNXT) climbed 107.8% to close at $16.02 on Monday after the company was granted FDA clearance for ‘Catheter, Intravascular Occluding, Temporary.’ The company recently priced its IPO at $9 per unit.